標的タンパク質分解の世界市場

標的タンパク質分解の世界市場は2030年までに14億米ドルに到達

2024年に5億2,820万米ドルと推定される標的タンパク質分解の世界市場は、2024年から2030年にかけてCAGR 17.9%で成長し、2030年には14億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるPROTACは、CAGR20.8%を記録し、分析期間終了時には5億9,880万米ドルに達すると予想されます。分子接着剤セグメントの成長率は、分析期間でCAGR 15.5％と推定されます。

米国市場は1億4,390万米ドルと推定、中国はCAGR24.8％で成長予測

米国の標的タンパク質分解市場は、2024年に1億4,390万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを24.8%として、2030年までに3億3,440万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ13.9%と16.1%と予測されています。欧州では、ドイツがCAGR約14.9%で成長すると予測されています。

世界の標的タンパク質分解市場- 主要動向と促進要因のまとめ

標的タンパク質分解が創薬と治療薬を再定義する理由とは？

標的タンパク質分解（TPD）は、創薬における最も有望なフロンティアの一つとして登場し、特にこれまで「治療不可能」であった標的を含む疾患の治療法に新たなパラダイムを提供しています。タンパク質の活性部位をブロックするだけの従来の低分子阻害剤とは異なり、TPDは細胞自身のタンパク質分解機構を活用し、病気の原因となるタンパク質をシステムから完全に除去します。このメカニズムにより、従来の薬理学の限界を超えて治療可能なプロテオームを拡大しながら、より深く、より長く治療効果を持続させる可能性があります。このアプローチの中心となるのは、PROTAC（プロテオリシス-ターゲッティング・キメラ）や分子接着剤などのヘテロ二官能性分子であり、プロテアソームによる破壊のためにE3ユビキチンリガーゼを標的タンパク質に作用させることによって、選択的分解を誘導する他の新しい手法です。この方法は、機能的な結合ポケットを必要とせず、足場となるタンパク質、転写因子、制御複合体-がん、神経変性疾患、免疫疾患-を分解することができます。治療上の意義は極めて大きく、研究者はこれまで見捨てられていた標的を再検討し、新たな生物学的経路を探索することができます。製薬会社、バイオテクノロジー・イノベーター、そして学術機関も同様に、TPDを単なるツールとしてではなく、革命的なプラットフォーム技術として捉え、この領域にリソースを注いでいます。最初の臨床段階のTPD治療が有望な結果を示し始めるにつれて、この分野は精密医療と疾患修飾の展望を再定義する態勢が整いつつあります。

技術革新はどのようにTPDモダリティとプラットフォームの進化を促しているのか？

標的タンパク質分解の分野は、TPDベースの治療薬の化学的多様性、送達効率、組織特異性を拡大する技術革新の波によって急速に変化しています。当初はサイズと生物学的利用能によって制限されていたプロタックは、現在ではリンカーの最適化、大環状足場、構造誘導設計技術によって、薬物動態を改善するように設計されています。一方、分子グルー-タンパク質間相互作用を誘導しユビキチン化を促進する低分子-は、構造がより単純で薬剤に類似した特性を持つことから、勢いを増しています。クライオ電子顕微鏡やNMR分光法を含む構造生物学の進歩により、分解剤の有効性において重要な要素である三元複合体の形成について、より明確な理解が可能になりつつあります。DNAコード化ライブラリー、CRISPRベースの機能ゲノミクス、高含量表現型アッセイなどの新しいスクリーニング・プラットフォームは、分解可能な標的を同定し、最適なE3リガーゼ・パートナーとマッチングさせるのに役立っています。これと並行して、組織特異的リガーゼと標的デリバリーシステムの開発が進められており、安全性プロファイルを向上させ、TPDの適用範囲を腫瘍学以外にも広げています。PROTACsのための抗体薬物複合体（ADC）やナノ粒子デリバリー・ビークルの使用も、特に脳や他の浸透しにくい組織を標的とするために研究中です。分解剤の有効性を予測し、規模に応じて化合物設計を最適化するために、人工知能や機械学習ツールの応用が進んでいます。これらの技術革新により、TPDは実験的なコンセプトから、幅広い疾患領域においてファースト・イン・クラスおよびベスト・イン・クラスの治療薬を生み出すことのできる多面的なプラットフォームへと急速に変貌しつつあります。

標的タンパク質分解はどこで最も強い臨床的・商業的インパクトを与えていますか？

標的タンパク質分解は、BRD4、BCL-XL、アンドロゲンまたはエストロゲン受容体など、多くの価値の高い標的が前臨床試験や初期の臨床試験で分解に成功している腫瘍学の分野で、最も即効性のあるインパクトを与えています。いくつかのPROTACベースの薬剤は、前立腺がん、乳がん、血液悪性腫瘍を標的とする候補を含め、ヒトでの臨床試験に入り、しばしば従来の阻害剤が失敗したり、耐性に遭遇した場合に有効性を示しています。がんに加えて、アルツハイマー病、パーキンソン病、ALSのような神経変性疾患は、阻害が困難であるが分解可能な可能性のある、ミスフォールド、凝集、あるいは本質的に無秩序なタンパク質が関与していることから、TPDの主要な機会領域です。自己免疫疾患や炎症性疾患も新たなターゲットであり、特にサイトカイン調節物質や細胞内免疫調節物質の分解剤が開発されています。大手製薬会社が分解剤の発見と最適化を専門とするバイオテクノロジー企業と数十億米ドル規模の提携を結ぶなど、商業的な状況は急速に拡大しています。Arvinas社、Kymera Therapeutics社、Nurix社、C4 Therapeutics社などの企業が臨床開発の主要企業であり、様々な治療領域にわたる有効なパイプラインを確立しています。臨床の枠を超え、学術研究センターがタンパク質機能と細胞生物学の研究にTPDツールを採用するケースが増えており、技術革新をさらに促進しています。地域的には、北米が初期段階の開発と資金調達を支配しているが、欧州とアジア太平洋は投資、規制当局との関与、機関との提携を強化しています。知的財産ポートフォリオが拡大し、第一世代の分解薬が規制当局の審査に近づくにつれて、TPDの商業的可能性はますます具体的になりつつあり、今後10年間の医薬品パイプラインのあり方に大きな変化をもたらす可能性を示しています。

世界標的タンパク質分解市場の急成長の原動力は？

世界の標的タンパク質分解市場の成長は、科学的ブレークスルー、アンメット・クリニカル・ニーズ、投資の勢い、治療用途の拡大が重なることによってもたらされます。中心的な原動力の一つは、従来の低分子化合物や生物製剤では対処できなかった疾患関連タンパク質の大部分にアクセスできるTPDの大きな能力です。より完全で耐久性のあるタンパク質サイレンシングが期待できることから、タンパク質の過剰発現や突然変異による病原性を特徴とする疾患の治療にとって、TPDは非常に魅力的な選択肢となります。がんや慢性疾患の世界の増加も、より選択的で耐性を回避する治療への需要を押し上げており、TPDが強い競争力を持つ分野です。ベンチャーキャピタルや戦略的製薬パートナーシップの流入は、パイプライン開発を加速させ、より多くの候補を臨床評価へと押し上げています。リガンド探索、リンカー化学、計算モデリング、ハイスループットスクリーニングの技術的進歩は、分解剤開発のスピードと成功率を高めています。規制当局もこうした新規メカニズムに関心を示しており、特定のプログラムに対してファスト・トラック指定や希少疾病用医薬品の優遇措置を提供し、商業化をさらに後押ししています。一方、細胞透過性で経口生物学的利用が可能な分解剤の利用可能性が高まるにつれ、これまでの採用障壁が克服されつつあります。学術研究と早期アクセス可能なTPDツールキットは、認知度を拡大し、非商業的な研究開発イニシアチブを可能にし、より豊かな創薬エコシステムを育んでいます。併用療法や組織特異的分解剤が普及し、新たなE3リガーゼが同定され利用されるにつれ、市場は急速に拡大し、標的タンパク質分解は精密治療やシステムレベルの治療の将来における中核的なモダリティとして位置づけられます。

セグメント

タイプ（PROTAC、Molecular Glues、LYTACs、その他）、用途（創薬、治療開発）、最終用途（製薬・バイオテクノロジー企業、学術・研究機関、病院・臨床研究所、その他）

調査対象企業の例

• Accutar Biotechnology
• AION Labs
• Amphista Therapeutics
• Arvinas, Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Bio-Techne Corporation
• Bristol-Myers Squibb Company
• C4 Therapeutics, Inc.
• Captor Therapeutics
• Cullgen Inc.
• Draupnir Bio
• F. Hoffmann-La Roche Ltd
• GSK plc
• Halda Therapeutics
• Kymera Therapeutics, Inc.
• Lycia Therapeutics
• Merck KGaA
• Monte Rosa Therapeutics
• Novartis International AG
• Nurix Therapeutics, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Targeted Protein Degradation Market to Reach US$1.4 Billion by 2030

The global market for Targeted Protein Degradation estimated at US$528.2 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 17.9% over the analysis period 2024-2030. PROTAC, one of the segments analyzed in the report, is expected to record a 20.8% CAGR and reach US$598.8 Million by the end of the analysis period. Growth in the Molecular Glues segment is estimated at 15.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$143.9 Million While China is Forecast to Grow at 24.8% CAGR

The Targeted Protein Degradation market in the U.S. is estimated at US$143.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$334.4 Million by the year 2030 trailing a CAGR of 24.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.9% and 16.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.9% CAGR.

Global Targeted Protein Degradation Market - Key Trends & Drivers Summarized

Why Is Targeted Protein Degradation Redefining Drug Discovery and Therapeutics?

Targeted protein degradation (TPD) has emerged as one of the most promising frontiers in drug discovery, offering a new paradigm in the way diseases-particularly those involving previously “undruggable” targets-can be treated. Unlike conventional small molecule inhibitors that merely block the active sites of proteins, TPD leverages the cell’s own protein degradation machinery to completely eliminate disease-causing proteins from the system. This mechanism offers the potential for deeper and longer-lasting therapeutic effects while expanding the druggable proteome beyond the limits of traditional pharmacology. Central to this approach are heterobifunctional molecules such as PROTACs (Proteolysis-Targeting Chimeras), molecular glues, and other novel modalities that induce selective degradation by recruiting E3 ubiquitin ligases to tag target proteins for proteasomal destruction. This method bypasses the need for a functional binding pocket and allows degradation of scaffolding proteins, transcription factors, and regulatory complexes-many of which are implicated in cancers, neurodegenerative diseases, and immune disorders. The therapeutic implications are profound, enabling researchers to revisit previously abandoned targets and explore new biological pathways. Pharmaceutical companies, biotech innovators, and academic institutions alike are pouring resources into this domain, seeing it not just as a tool, but as a revolutionary platform technology. As the first clinical-stage TPD therapies begin to show encouraging results, the field is poised to redefine the landscape of precision medicine and disease modification.

How Are Technological Innovations Driving the Evolution of TPD Modalities and Platforms?

The field of targeted protein degradation is being rapidly transformed by a wave of technological innovation, which is expanding the chemical diversity, delivery efficiency, and tissue specificity of TPD-based therapeutics. PROTACs, initially limited by size and bioavailability, are now being engineered with improved pharmacokinetics through linker optimization, macrocyclic scaffolds, and structure-guided design techniques. Meanwhile, molecular glues-small molecules that induce protein-protein interactions to promote ubiquitination-are gaining momentum due to their simpler structures and favorable drug-like properties. Advances in structural biology, including cryo-EM and NMR spectroscopy, are enabling a clearer understanding of ternary complex formation, a critical factor in the efficacy of degraders. New screening platforms, such as DNA-encoded libraries, CRISPR-based functional genomics, and high-content phenotypic assays, are helping identify degradable targets and match them with optimal E3 ligase partners. In parallel, tissue-specific ligases and targeted delivery systems are being developed to enhance safety profiles and expand TPD’s applicability beyond oncology. The use of antibody-drug conjugates (ADCs) and nanoparticle delivery vehicles for PROTACs is also under investigation, particularly for targeting the brain and other difficult-to-penetrate tissues. Artificial intelligence and machine learning tools are increasingly being applied to predict degrader efficacy and optimize compound design at scale. These innovations are rapidly converting TPD from an experimental concept into a multi-faceted platform capable of producing first-in-class and best-in-class therapeutics across a wide spectrum of diseases.

Where Is Targeted Protein Degradation Making the Strongest Clinical and Commercial Impact?

Targeted protein degradation is making its most immediate impact in the field of oncology, where many high-value targets-such as BRD4, BCL-XL, and androgen or estrogen receptors-have been successfully degraded in preclinical and early clinical studies. Several PROTAC-based drugs have entered human trials, including candidates targeting prostate cancer, breast cancer, and hematologic malignancies, often showing efficacy where traditional inhibitors have failed or encountered resistance. In addition to cancer, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS represent a major area of opportunity for TPD, given the involvement of misfolded, aggregated, or intrinsically disordered proteins that are difficult to inhibit but potentially degradable. Autoimmune and inflammatory diseases are also emerging targets, particularly as degraders are developed for cytokine modulators and intracellular immune regulators. The commercial landscape is expanding rapidly, with major pharmaceutical companies entering multi-billion-dollar partnerships with biotech firms that specialize in degrader discovery and optimization. Companies like Arvinas, Kymera Therapeutics, Nurix, and C4 Therapeutics are leading clinical development efforts and have established validated pipelines spanning various therapeutic areas. Beyond the clinical setting, academic research centers are increasingly adopting TPD tools to study protein function and cellular biology, further driving innovation. Geographically, North America dominates early-stage development and funding, but Europe and Asia-Pacific are ramping up investment, regulatory engagement, and institutional collaborations. As intellectual property portfolios grow and first-generation degrader drugs approach regulatory review, the commercial potential of TPD is becoming increasingly tangible, signaling a major shift in how drug pipelines may be shaped in the coming decade.

What’s Fueling the Rapid Growth of the Global Targeted Protein Degradation Market?

The growth of the global targeted protein degradation market is driven by a confluence of scientific breakthroughs, unmet clinical needs, investment momentum, and broadening therapeutic applications. One of the core drivers is the significant ability of TPD to access the large swath of disease-related proteins that have remained unaddressable by conventional small molecules and biologics. The promise of more complete and durable protein silencing makes it a highly attractive option for treating diseases characterized by protein overexpression or mutation-driven pathogenicity. Rising incidence of cancers and chronic illnesses globally is also pushing demand for more selective, resistance-evading therapies-an area where TPD has strong competitive advantage. The influx of venture capital and strategic pharmaceutical partnerships is accelerating pipeline development and pushing more candidates into clinical evaluation. Technological advancements in ligand discovery, linker chemistry, computational modeling, and high-throughput screening are increasing the speed and success rate of degrader development. Regulatory agencies are also showing interest in these novel mechanisms, offering fast-track designations and orphan drug incentives for certain programs, further supporting commercialization. Meanwhile, the growing availability of cell-permeable, orally bioavailable degraders is overcoming previous barriers to adoption. Academic research and early-access TPD toolkits are expanding awareness and enabling non-commercial R&D initiatives, fostering a richer discovery ecosystem. As combination therapies and tissue-specific degraders gain traction, and new E3 ligases are identified and harnessed, the market is set to expand rapidly-positioning targeted protein degradation as a core modality in the future of precision and systems-level therapeutics.

SCOPE OF STUDY:

The report analyzes the Targeted Protein Degradation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (PROTAC, Molecular Glues, LYTACs, Others); Application (Drug Discovery, Therapy Development); End-Use (Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Clinical Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Accutar Biotechnology
• AION Labs
• Amphista Therapeutics
• Arvinas, Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Bio-Techne Corporation
• Bristol-Myers Squibb Company
• C4 Therapeutics, Inc.
• Captor Therapeutics
• Cullgen Inc.
• Draupnir Bio
• F. Hoffmann-La Roche Ltd
• GSK plc
• Halda Therapeutics
• Kymera Therapeutics, Inc.
• Lycia Therapeutics
• Merck KGaA
• Monte Rosa Therapeutics
• Novartis International AG
• Nurix Therapeutics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Targeted Protein Degradation - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Interest in Novel Modalities Throws the Spotlight on Targeted Protein Degradation as a Transformative Therapeutic Strategy
  • Unmet Need for Treating Undruggable Proteins Propels Growth in the Development of PROTACs and Molecular Glues
  • Expansion of Precision Oncology Strengthens the Business Case for Targeted Protein Degraders in Tumor-Specific Therapies
  • Advancements in E3 Ligase Biology and Ligand Discovery Drive Innovation in Degrader Platform Technologies
  • Increased Focus on Oral Bioavailability and Pharmacokinetics Accelerates Development of Next-Generation Small Molecule Degraders
  • Growing Pipeline of First-in-Class Candidates Expands the Addressable Market Across Oncology, Immunology, and Neurology
  • Improved Structural Biology and AI-Based Drug Design Enhance the Selectivity and Potency of Targeted Degradation Therapies
  • Rising Regulatory Support and Orphan Drug Incentives Spur Fast-Track Development of Protein Degradation Therapeutics
  • Integration of TPD into Multi-Target and Combination Therapy Strategies Drives Interest in Personalized Cancer Treatment
  • Application of Targeted Degraders in CNS Disorders and Autoimmune Diseases Unlocks New Long-Term Growth Opportunities
  • Emergence of Molecular Glue Degraders with Simplified Structures Supports Scalability and Broad Therapeutic Exploration
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Targeted Protein Degradation Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Targeted Protein Degradation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Targeted Protein Degradation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Targeted Protein Degradation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for PROTAC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for PROTAC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for PROTAC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Molecular Glues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Molecular Glues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Molecular Glues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for LYTACs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for LYTACs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for LYTACs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals & Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals & Clinical Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Therapy Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Therapy Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Therapy Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• JAPAN
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• CHINA
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• EUROPE
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Targeted Protein Degradation by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Targeted Protein Degradation by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Targeted Protein Degradation by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• FRANCE
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• GERMANY
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Protein Degradation by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Targeted Protein Degradation by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Targeted Protein Degradation by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• INDIA
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Targeted Protein Degradation by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Targeted Protein Degradation by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Targeted Protein Degradation by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Targeted Protein Degradation by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Targeted Protein Degradation by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Targeted Protein Degradation by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030
• AFRICA
  • Targeted Protein Degradation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Targeted Protein Degradation by Type - PROTAC, Molecular Glues, LYTACs and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Targeted Protein Degradation by Type - Percentage Breakdown of Value Sales for PROTAC, Molecular Glues, LYTACs and Other Types for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Targeted Protein Degradation by End-Use - Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Targeted Protein Degradation by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Pharma & Biotech Companies, Academic & Research Institutes and Hospitals & Clinical Laboratories for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Targeted Protein Degradation by Application - Drug Discovery and Therapy Development Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Targeted Protein Degradation by Application - Percentage Breakdown of Value Sales for Drug Discovery and Therapy Development for the Years 2015, 2025 & 2030

IV. COMPETITION